Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Gastroenteritis, Hepatitis, Encephalopathy, and Human Herpesvirus 6 Detection in an Immunocompetent Child: Benefits and Risks of Syndromic Multiplex Molecular Panel Testing

Christina A. Olson, MD1,2, Samuel R. Dominguez, MD, PhD1,2, Steve Miller, MD, PhD3, Charles Y. Chiu, MD, PhD3,4,5, and Kevin Messacar, MD1,2

An immunocompetent toddler came to medical attention with gastroenteritis, complicated by encephalopathy and hepatitis. Multiplexed testing using a polymerase chain reaction meningitis panel was positive for human herpesvirus 6 (HHV-6). Clinical correlation, quantitative HHV-6 polymerase chain reaction, and metagenomic next-generation sequencing supported a likely diagnosis of primary HHV-6B infection. (J Pediatr 2019;212:228-31).

Human herpesvirus 6 (HHV-6) infects 90% of children by 2 years of age1 and accounts for 10% of visits to the emergency department for febrile illness in the first 3 years.2 The classic presentation is a self-limited high fever followed by a rash, the illness known as roseola infantum or sixth disease.3 The rapid temperature rise also can be associated with seizures, accounting for one-third of febrile seizures before 2 years of age.1 In immunocompromised patients, HHV-6 is a well-recognized cause of severe disease.4-6 In clinical practice, however, the frequency and potential for severe HHV-6 infection in immunocompetent children is likely under-recognized because of a lack of routine clinical testing.

HHV-6 has been included in a multiplex polymerase chain reaction (PCR) meningitis/encephalitis panel for pathogen detection from cerebrospinal fluid (CSF) (BioFire FilmArray Meningitis/Encephalitis (ME) panel; BioMérieux).7 Multiplexed testing has the potential to identify a broader clinical spectrum of acute infection in immunocompetent children, as testing for HHV-6 alone is rarely pursued. Results must be interpreted cautiously, however, because qualitative DNA detection alone is insufficient evidence for active infection.8 Clinical judgment and consideration of secondary quantitative DNA testing (in the CSF, serum and/or whole blood) is required when HHV-6 is detected in CSF on a syndromic multiplex PCR panel. We describe a previously healthy child with severe gastroenteritis, hepatitis, and encephalopathy because of probable primary HHV-6B infection, a constellation of symptoms predominantly described in immunocompromised patients.

Case

A 13-month-old male child came to medical attention with vomiting, diarrhea, and dehydration. His past medical history was unremarkable. There were no prior hospitalizations, unusual infections, or concerns about growth. A sibling was ill with similar but milder symptoms, and there was no concerning travel, food, or animal exposure history.

Following hospitalization with a diagnosis of viral gastroenteritis and failure of oral fluid challenge, he developed fever and prolonged somnolence but no meningeal signs, seizures, or focal neurologic deficits. He also failed several trials of intravenous fluids, with associated deterioration in perfusion and alteration in mental status.

A blood gas, comprehensive serum metabolic panel, complete blood count, and abdominal radiographs were performed on hospital day 2, and all results were unremarkable. Because of ongoing symptoms, the laboratory tests were repeated on hospital day 5; in the interim, his white blood cell count had doubled, platelet count had dropped, and serum hepatic transaminases, lactate dehydrogenase, and ferritin had increased markedly. Testing for erythrocyte sedimentation rate, C-reactive protein, liver function, acetaminophen level, lactate and triglyceride levels, inborn errors of metabolism, cortisol, and antinuclear antibodies were normal, as was an echocardiogram and brain magnetic resonance imaging. Peripheral blood smears showed no evidence of malignancy or hemophagocytosis (Table).

A stool PCR panel (BioFire FilmArray gastrointestinal panel; BioMérieux) was positive for Clostridium difficile, but testing of nasal washings for respiratory pathogens (BioFire FilmArray respiratory pathogen panel), serum for...
infection because of Epstein-Barr virus viral capsid antigen IgG/IgM, hepatitis A virus IgM, hepatitis E virus IgM, and parvovirus IgM, as well as blood, urine, and CSF bacterial cultures were negative. A CSF PCR panel (BioFire FilmArray ME panel, Bio-Mérieux) obtained on hospital day 6, performed on a CSF specimen with 3 white blood cells/μL, 0 red blood cells/μL, and normal protein and glucose, was positive for HHV-6. All other panel targets, including enterovirus, parechovirus, and herpes simplex virus, were negative. Follow-up quantitative HHV-6 PCR testing on the CSF and serum were remarkable for HHV-6 viral loads of 21,630 copies/mL and 146,340 copies/mL, respectively (Table 1). Clinical metagenomic next-generation sequencing (mNGS) of CSF was performed, which detected 4517 sequence reads spanning 67% of the genome of HHV-6, confirmed as subtype B (HHV-6B) by phylogenetic analysis (Figure); no other bacterial, viral, parasitic, or fungal pathogen was detected by mNGS. The patient developed a viral exanthem on hospital day 7 with defervescence, further supporting a diagnosis of primary HHV-6 infection. His state of alertness and well-being, examination, and laboratory abnormalities improved with supportive care, and he was discharged on hospital day 13.

Discussion

HHV-6 generally is considered a benign infection in immunocompetent children, but this case suggests that HHV-6 should be considered in otherwise healthy patients with clinical manifestations of more severe illness, such as gastro-enteritis, hepatitis, and/or encephalopathy. Though not commonly associated with these clinical conditions, studies show that children with HHV-6 are more likely to have diarrhea than age-matched controls (26% vs 11% P = .05), and hepatitis has been associated with HHV-6 in infants and stem-cell and solid organ transplant patients.

This case also demonstrates that liver and central nervous system involvement may not be present initially, warranting repeated laboratory testing if symptoms persist beyond a few days. Although this patient lacked features for an encephalitis diagnosis according to International Encephalitis Consortium criteria (seizures, focal neurologic abnormalities, pleocytosis, neuroimaging changes), the presence of HHV-6 DNA in the CSF was associated with encephalopathy without an alternative explanation (broad-based CSF multiplex PCR and mNGS testing were negative for other pathogens). Normal CSF white blood cell counts are well-described in HHV-6 central nervous system infection, which supports a role for HHV-6 testing in the setting of encephalopathy regardless of pleocytosis.

Table 1. Selected laboratory testing

| Laboratory studies | Hospital day 2 result | Hospital day 5 result | Reference values/units |
|--------------------|-----------------------|-----------------------|------------------------|
| White blood cell count | 6.9 | 14.2 | 7.7-13.7 × 10^9/μL |
| Neutrophils | 46 | 38 | % |
| Bands | 22 | 0.4 | % |
| Lymphocytes | 21 | 56 | % |
| Hemoglobin | 11.2 | 11.2 | 10.3-13.8 g/dL |
| Platelet count | 278 | 97 | 150-500 × 10^9/μL |
| Erythrocyte sedimentation rate | 1 | <0.5 | 0-15 mm/h |
| C-reactive protein | 1920 | 10-60 mg/dL |
| Ferritin | 3896 | 500-920 U/L |
| Lactate dehydrogenase | 0.2 | 0.2 | 0.2-1.2 mg/dL |
| Total bilirubin | 131 | 163 | 129-291 U/L |
| Alkaline phosphatase | 32 | 1053 | 20-60 U/L |
| Aspartate aminotransferase | 21 | 482 | 5-45 U/L |
| Alanine aminotransferase | 21 | 482 | 5-45 U/L |
| Stool PCR panel
  Clostridium difficile detected*
  Respiratory PCR panel
  No target detected†
  CSF PCR panel
  HHV-6 detected‡
| HHV-6 quantitative PCR tests
  CSF: 21,630 copies/mL (no reference range)
  Serum: 146,340 copies/mL (no reference range) |

*Cryptosporidium, Cyclospora cayetanensis, Entamoeba histolytica, Giardia lamblia, adenovirus, astrovirus, norovirus, rotavirus, sapovirus, Campylobacter spp, Escherichia coli spp, Shigella spp, Salmonella spp, Yersinia enterocolitica, Vibrio spp not detected.
†Adenovirus, coronavirus, human metapneumovirus, rhinovirus, enterovirus, influenza, parainfluenza, respiratory syncytial virus, pertussis, Mycoplasma pneumoniae, Chlamydia pneumoniae not detected.
‡Escherichia coli, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus agalactiae, Streptococcus pneumoniae, Cryptococcus spp, cytomegalovirus, enterovirus, herpes simplex virus, parechovirus not detected.
patients, their detection usually is unrelated to the primary cause of disease in immunocompetent hosts.

Additional laboratory studies are available to distinguish chromosomally integrated HHV-6 DNA from active or reactivated infection. For example, a whole blood quantitative PCR result greater than 5.5 log copies/mL of blood or serial tests showing persistently high levels of HHV-6 DNA over time support a diagnosis of chromosomal integration. Acute and convalescent serologic testing is another method to distinguish active infection from reactivation or chromosomally integrated DNA. However, serial testing may be unavailable or impractical for use in the clinical setting, particularly when a timely diagnosis is needed. This patient’s young age made reactivation unlikely, and his eventual development of a characteristic roseola-type exanthem with self-resolution of fever was highly consistent with primary HHV-6 infection. As a result, definitive laboratory confirmation was not performed.

Besides describing a unique constellation of symptoms in an immunocompetent patient with likely primary HHV-6 infection, this case demonstrates both the advantages and challenges associated with the clinical use of multiplexed testing such as syndromic multiplex PCR panels or mNGS. Detection of nucleic acid from a pathogen consistent with the clinical presentation, such as HHV-6 in this case, can support a diagnosis that informs management and limits unnecessary testing or treatment. However, nonpathogenic organism detection may lead to incorrect assumptions of cause-and-effect, increase utilization of ineffectual and potentially harmful therapies, and impede evaluation and management of the true diagnosis. This patient’s positive Clostridium difficile PCR result most likely represented...
colonization based on his age, and lack of diarrhea with blood or mucous in stools or recent antibiotic use. Multiplex test results should be interpreted in the clinical context with consideration of the pre-test probability for each potential pathogen detected.

We thank the Children’s Hospital Colorado microbiology laboratory staff who coordinated the additional laboratory testing.

Submitted for publication Jan 12, 2019; last revision received Apr 23, 2019; accepted Apr 28, 2019.

Reprint requests: Christina A. Olson, MD, Children’s Hospital Colorado, 13123 E 16th Ave, B270, Aurora, CO 80045. E-mail: Christina.olson@childrenscolorado.org

References

1. Zerr DM, Meier AS, Selke SS, Frankel LM, Huang M, Wald A, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med 2005;352:768-76.
2. Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994;331:432-8.
3. Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988;1:1065-7.
4. Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. Bone Marrow Transplant 2015;50:1030-6.
5. Fotheringham J, Akhyani N, Vortmeyer A, Donati D, Williams E, Oh U, et al. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis 2007;195:430-4.
6. Seeley WW, Marty FM, Holmes TM, Upchurch K, Soiffer RJ, Antin JH, et al. Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology 2007;69:156-65.
7. Leber AL, Everhart K, Balada-Llasat JM, Cullison J, Daly J, Holt S, et al. Multicenter evaluation of the BioFire FilmArray meningitis encephalitis panel for the detection of bacteria, viruses and yeast in cerebrospinal fluid specimens. J Clin Microbiol 2016;54:2251-61.
8. Green DA, Pereira M, Miko B, Radmard S, Whittier S, Thakur K. Clinical significance of human herpesvirus 6 positivity on the FilmArray meningitis/encephalitis panel. Clin Infect Dis 2018;67:1125-8.
9. Naccache SN, Federman S, Veeraraghavan N, Zaharia M, Lee D, Samayoa E, et al. A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples. Genome Res 2014;24:1180-92.
10. Mendel I, de Matteis M, Bartin C, Delaporte B, Maguer D, Collandre H, et al. Fulminant hepatitis in neonates with human herpesvirus 6 infection. Pediatr Infect Dis J 1995;14:993-7.
11. Asano Y, Nakashima T, Yoshikawa T, Suga S, Yazaki T. Severity of human herpesvirus-6 viremia and clinical findings in infants with exanthem subitum. J Pediatr 1991;118:891-5.
12. Hill JA, Myerson D, Sedlak RH, Jerome KR, Zerr DM. Hepatitis due to human herpesvirus 6B after hematopoietic cell transplantation and a review of the literature. Transpl Infect Dis 2014;16:477-83.
13. Yoshikawa T. Human herpesvirus 6 causes hepatitis in transplant recipients. Intern Med 2006;45:417-8.
14. Venkatesan A, Tunkel AR, Bloch KC, Lauring AS, Sejvar J, Bittun A, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis 2013;57:1114-28.
15. Kauffer BB, Flaman L. Chromosomally integrated HHV-6: impact on virus, cell and organismal biology. Curr Opin Virol 2014;9:111-8.
16. Ward KN, Leong HN, Thiruchelvam AD, Atkinson CE, Clark DA. Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis. J Clin Microbiol 2007;45:1298-304.
17. Ogata M, Satou T, Kadota J, Saito N, Yoshida T, Okumura H, et al. Human herpesvirus 6 (HHV-6) reactivation and HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: a multicenter, prospective study. Clin Infect Dis 2013;57:671-81.
18. Pellett PE, Ablashi DV, Ambros PF, Agut H, Caserta MT, Descamps V, et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol 2012;22:144-55.
19. Shim JO. Clostridium difficile in children: to treat or not to treat? Pediatr Gastroenterol Hepatol Nutr 2014;17:80-4.